UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (publ) (STO:ORX) announces today that Boehringer Ingelheim has decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Boehringer Ingelheim has since 2005 been responsible for all research and development within the OX-MPI project.
Help employers find you! Check out all the jobs and post your resume.
